Synthesis and structure-activity relationships of novel benzofuran farnesyltransferase inhibitors

Kohsuke Asoh1, Masami Kohchi, Ikumi Hyoudoh

  • 1Kamakura Research Laboratories, Chugai Pharmaceutical Co. Ltd., 200-Kajiwara, Kamakura, Kanagawa 247-8530, Japan.

Insights

Researchers developed novel benzofuran compounds as potential antitumor drugs. Compound 11f demonstrated significant farnesyltransferase inhibition and anticancer effects in preclinical models.

Area of Science:

  • Medicinal Chemistry
  • Drug Discovery
  • Oncology

Background:

  • Farnesyltransferase is a key enzyme in cancer cell signaling pathways.
  • Developing targeted inhibitors is crucial for effective cancer therapy.
  • Benzofuran scaffolds offer a promising structural basis for novel drug design.

Purpose of the Study:

  • To design and synthesize novel benzofuran-based compounds.
  • To evaluate their potential as farnesyltransferase inhibitors.
  • To assess their antitumor efficacy in preclinical cancer models.

Main Methods:

  • Synthesis of a series of benzofuran derivatives.
  • In vitro enzyme inhibition assays to determine IC(50) values.
  • In vivo studies using human cancer xenografts in mice.

Main Results:

  • Compound 11f exhibited the most potent enzyme inhibitory activity with an IC(50) of 1.1 nM.
  • Compound 11f demonstrated significant antitumor activity in mouse models of human cancer.
  • Structure-activity relationship analysis guided the optimization of inhibitor potency.

Conclusions:

  • Benzofuran-based compounds are effective inhibitors of farnesyltransferase.
  • Compound 11f represents a promising lead candidate for anticancer drug development.
  • Further investigation of compound 11f is warranted for clinical translation.

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship01:29

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic antagonists are called...
Electrophilic Aromatic Substitution: Fluorination and Iodination of Benzene01:13

Electrophilic Aromatic Substitution: Fluorination and Iodination of Benzene

Bromination and chlorination of aromatic rings by electrophilic aromatic substitution reactions are easily achieved, but fluorination and iodination are difficult to achieve. Fluorine is so reactive that its reaction with benzene is difficult to control, resulting in poor yields of monofluoroaromatic products. To address this, Selectfluor reagent is used as a fluorine source in which a fluorine atom is bonded to a positively charged nitrogen.